ConductScience.org, home

Paper39635534

COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.

He N and 5 others. Front Immunol, 2024. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity. Papers, record 39635534. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39635534

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
COVID-19 mitigates the response to TKIs in patients with CML via the inhibition of T-cell immunity.
PubMed
Journal
Front Immunol
PubMed
Year
2024
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
0
iCite
Relative citation ratio, by iCite
0.0, provisional
iCite
Revised in PubMed
2026-09-25
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1He NNa
2Li GGuosheng
3Liu JJinting
4Liu WWancheng
5Tian RRuifeng
6Ma DDaoxin

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Leukemia, Myelogenous, Chronic, BCR-ABL PositiveMajor topic
COVID-19Major topic
Protein Kinase InhibitorsMajor topic
SARS-CoV-2Major topic
Fusion Proteins, bcr-ablMajor topic
Humans
Male
Female
Middle Aged
Adult
Aged
T-Lymphocytes

Source PubMed

Download CSV of topics

References25

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135818053A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase.J Hematol Oncol2022https://conductscience.org/library/papers/35818053PubMed
235068289Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study.Leuk Lymphoma2022https://conductscience.org/library/papers/35068289PubMed
332998157COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses.Nature2020https://conductscience.org/library/papers/32998157PubMed
433435150Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future.Cells2021https://conductscience.org/library/papers/33435150PubMed
536276065Impact of the COVID-19 pandemic on the regular follow-up and outcomes of patients with chronic myeloid leukemia in chronic-phase.Front Oncol2022https://conductscience.org/library/papers/36276065PubMed
636580318Association of COVID-19 Vaccination With Breakthrough Infections and Complications in Patients With Cancer.JAMA Oncol2023https://conductscience.org/library/papers/36580318PubMed
728359029Is there immune surveillance against chronic myeloid leukaemia? Possibly, but not much.Leuk Res2017https://conductscience.org/library/papers/28359029PubMed
832424293COVID-19 in persons with chronic myeloid leukaemia.Leukemia2020https://conductscience.org/library/papers/32424293PubMed
932066541Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.Lancet Oncol2020https://conductscience.org/library/papers/32066541PubMed
1033168949Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets.Leukemia2021https://conductscience.org/library/papers/33168949PubMed
1135619871Tumor Lysis Syndrome in the Chronic Phase of Chronic Myeloid Leukemia Following COVID-19 Infection: A Case Report.Cureus2022https://conductscience.org/library/papers/35619871PubMed
1236125379Pulmonary Dysfunction after Pediatric COVID-19.Radiology2023https://conductscience.org/library/papers/36125379PubMed
1335176326COVID-19 in dialysis: clinical impact, immune response, prevention, and treatment.Kidney Int2022https://conductscience.org/library/papers/35176326PubMed
1433014780Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2.Front Oncol2020https://conductscience.org/library/papers/33014780PubMed
1517032128Westgard multirule for calculated laboratory tests.Clin Chem Lab Med2006https://conductscience.org/library/papers/17032128PubMed
1632839569Not just antibodies: B cells and T cells mediate immunity to COVID-19.Nat Rev Immunol2020https://conductscience.org/library/papers/32839569PubMed
1732866033Uncontrolled Innate and Impaired Adaptive Immune Responses in Patients with COVID-19 Acute Respiratory Distress Syndrome.Am J Respir Crit Care Med2020https://conductscience.org/library/papers/32866033PubMed
1834182569SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.Nature2021https://conductscience.org/library/papers/34182569PubMed
1931289206Human BCR/ABL1 induces chronic myeloid leukemia-like disease in zebrafish.Haematologica2020https://conductscience.org/library/papers/31289206PubMed
2034708401Is COVID-19 less severe in CML patients than in those with other haematological cancers?Br J Haematol2022https://conductscience.org/library/papers/34708401PubMed

See all 25 referencesDownload CSV of references

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ABL125PubTator's text mininghttps://conductscience.org/library/genes/25NCBI Gene
CD8A925PubTator's text mininghttps://conductscience.org/library/genes/925NCBI Gene
TXK7294PubTator's text mininghttps://conductscience.org/library/genes/7294NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39635534

GET https://conductscience.org/api/papers/v1/39635534/references?page=2